Chronic Inducible Urticaria is a condition where hives occur from specific triggers such as touch (scratching) or exposure to heat or cold temperatures, causing itchy skin, hives, and rashes. Researchers are testing a new treatment called EVO756 in a study to see if it can reduce hives in people who are affected with this condition. EVO756 may offer a new way to treat hives with a capsule-form taken orally once a day.
We are currently recruiting participants 18 to 65 years, with a medical diagnosis of hives that is triggered by touch or cold temperatures. We are investigating the safety and effectiveness of EVO756.
What’s involved:
- Study Duration: Approximately 10 weeks.
- Process: Includes a 30-day screening period, 4 weeks of treatment, and a 2-week follow-up after your last dose.
- Open-Label Study: Participants are guaranteed to receive EVO756.
- Visits: Each visit takes 2 to 4 hours, depending on necessary tests.
- Medical Tests: Includes blood samples, electrocardiograms, and vital signs at various visits.
- Compensation: Financial compensation may be available for time and travel.
- Cost: No cost for participation; study medication and related medical care provided.
Get Involved: Help advance medical research and receive care throughout the study. Join us in exploring an investigational treatment for hives triggered by touch or cold temperatures.
